<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00706680</url>
  </required_header>
  <id_info>
    <org_study_id>07-0619-A</org_study_id>
    <nct_id>NCT00706680</nct_id>
  </id_info>
  <brief_title>Thymoglobulin in Calcineurin Inhibitor and Steroid Minimization Protocol</brief_title>
  <official_title>The Use of Thymoglobulin in a Calcineurin Inhibitor and Steroid Minimization Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Michael's Hospital, Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Paul's Hospital, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has been designed to test whether using Thymoglobulin with low dose Cyclosporine
      and early steroid dosage reduction will minimize both kidney rejection and the development of
      new onset diabetes mellitus after renal transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients will receive methyl prednisone intravenously pre-operatively, as per
      institutional practice. Thymoglobulin will be initiated prior to completion of the
      anastomosis, or if not possible, within 24 hours of transplantation in all patients and a
      total dose of 6-7.5mg/kg will be given over 3-5 doses. Steroids will be initiated
      post-operatively at 1mg/kg/day for 2 days, then 0.5mg/kg/day for 2 days, then 0.25mg/kg/day
      for 2 days and then patients will be placed on 5mg daily for the remainder of the study. All
      patients will receive Mycophenolic acid at a dose of 2gm/day (Cellcept) or 1440mg/day
      (Myfortic) post-transplantation with dose adjustment as needed. Cyclosporine micro-emulsion
      will be initiated when renal function is established or no later than day 10 in a dose of
      3mg/kg twice daily with adjustment to achieve a C2 target of 600-800 nanograms/ml.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2008</start_date>
  <completion_date type="Anticipated">June 2009</completion_date>
  <primary_completion_date type="Anticipated">February 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients developing New Onset Diabetes post transplant, as identified by an oral glucose tolerance test</measure>
    <time_frame>6 months post transplant.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute rejection</measure>
    <time_frame>6 months post transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Diabetes</condition>
  <condition>Graft Rejection</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects meeting the entry criteria will be treated with the study immunosuppressive protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <description>methyl prednisone intravenously pre-operatively, as per institutional practice. Thymoglobulin, initiated prior to completion of the anastomosis, or if not possible, within 24 hours of transplantation for a total dose of 6-7.5mg/kg given over 3-5 doses. Steroids initiated post-operatively at 1mg/kg/day for 2 days, then 0.5mg/kg/day for 2 days, then 0.25mg/kg/day for 2 days. Patients will be placed on 5mg daily for the remainder of the study. All patients will receive Mycophenolic acid at a dose of 2gm/day (Cellcept) or 1440mg/day (Myfortic) post-transplantation with dose adjustment as needed. Cyclosporine micro-emulsion will be initiated when renal function is established or no later than day 10 in a dose of 3mg/kg twice daily with adjustment to achieve a C2 target of 600-800 nanograms/ml.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Thymo</other_name>
    <other_name>Polyclonal ATG</other_name>
    <other_name>Methyl Prednisone</other_name>
    <other_name>SoluMedrol</other_name>
    <other_name>Steroid</other_name>
    <other_name>Prednisone</other_name>
    <other_name>MMF</other_name>
    <other_name>Cell Cept</other_name>
    <other_name>Mycophenolate Mofetil</other_name>
    <other_name>Mycopnlolic Acid</other_name>
    <other_name>Myfortic</other_name>
    <other_name>Cyclosporine</other_name>
    <other_name>Neoral</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  De Novo, single Kidney recipient

          -  At least 1 HLA mismatch

        Exclusion Criteria:

          -  Recipient of multiple organs

          -  prior transplant recipient

          -  Subjects who have Diabetes prior to transplant, as indicated by pre-transplant OGTT

          -  PRA &gt;10%

          -  Hepatitis B surface antigen positive

          -  Hepatitis C antibody positive

          -  HIV positive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Cole</last_name>
    <role>Study Director</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Gill</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Paul's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ramesh Prasad</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Michael's Hospital, Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Edward Cole</last_name>
    <phone>416-340-4800</phone>
    <phone_ext>4669</phone_ext>
    <email>edward.cole@uhn.on.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bricio Rodriguez</last_name>
    <phone>416-340-4800</phone>
    <phone_ext>5921</phone_ext>
    <email>bricio.rodriguez@uhn.on.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2E8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Gill</last_name>
      <phone>604-681-7191</phone>
    </contact>
    <investigator>
      <last_name>John Gill</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Landsberg</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5C 2T2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ramesh Prasad</last_name>
      <phone>(416) 867-3722</phone>
      <email>Ramesh.Prasad@utoronto.ca</email>
    </contact>
    <investigator>
      <last_name>Ramesh Prasad</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey Zaltzman</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bricio Rodriguez</last_name>
      <phone>416-340-4800</phone>
      <phone_ext>5921</phone_ext>
      <email>bricio.rodriguez@uhn.on.ca</email>
    </contact>
    <investigator>
      <last_name>Carl Cardella</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edward Cole</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2008</study_first_submitted>
  <study_first_submitted_qc>June 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2008</study_first_posted>
  <last_update_submitted>June 25, 2008</last_update_submitted>
  <last_update_submitted_qc>June 25, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Edward Cole</name_title>
    <organization>University Health Network</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

